ICYMI: American Society for Clinical Oncology statement on clinical pathways
Clinical pathways need to be carefully developed to support informed choices by health care providers and their patients.
Clinical pathways need to be carefully developed to support informed choices by health care providers and their patients.
Last week, the American Society for Clinical Oncology (ASCO) issued a policy statement calling for improvements in clinical pathway programs. The statement responds to the growing concern that clinical pathways are being developed and implemented in a way that could impede delivery of high-quality cancer care.
ASCO offers several recommendations to improve the development and use of clinical pathways in oncology:
These recommendations echo many of the concerns expressed by members of the patient community and underscore the need for pathways to be carefully developed to support informed choices by health care providers and their patients.
To learn more about clinical pathways and what they mean for treatment options, check out recent research from Avalere Health, or view PhRMA’s principles for clinical pathway programs.